Fredrik Schjesvold - Concepedia

Author

Fredrik Schjesvold

Also Known As

Abildgaard , Niels, Emil Hermansen, F Schjesvold, F. H. Schjesvold, F. Schjesvold, F.H. Schjesvold, Fredrik H Schjesvold, Fredrik H. Schjesvold, Fredrik Hellem Schjesvold, Fredrik Schjesvold

293

Publications

7.6K

Citations

H-Index

Concepts

All Affiliations

Oslo University Hospital University of Oslo National and Kapodistrian University of Athens Clinica Universidad de Navarra Erasmus MC Cancer Institute

About

Fredrik Schjesvold is an author at Oslo University Hospital specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	23	4.2K
2	Health Sciences	13	14	1.9K
3	Cell Biology	2	2	37
4	Cellular Therapies	2	3	497
5	Clinical Immunology	2	2	48

Fredrik Schjesvold

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† Meletios Α. Dimopoulos, Philippe Moreau, Evangelos Terpos, Annals of Oncology Hematological MalignancyOncologyHematologyMyeloid NeoplasiaMultiple Myeloma	2021	782
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study Michel Attal, Paul G. Richardson, S. Vincent Rajkumar, The Lancet Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy	2019	620
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro, New England Journal of Medicine	2023	435
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Paul G. Richardson, Albert Oriol, Meral Beksaç, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2019	375
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, The Lancet Haematology Hematological MalignancyOncologyHematologyImmunologyImmune Checkpoint Inhibitor	2019	249
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, The Lancet Haematology Hematological MalignancyMedicineImmunologyClinical TrialsHematology	2019	237
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold, The Lancet Regenerative MedicineCell TherapyTransplantationMarrow TransplantationPlacebo-controlled Phase 3	2018	231
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage Carlos Fernández de Larrea, Robert A. Kyle, Laura Rosiñol, Blood Cancer Journal	2021	164
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Meletios Α. Dimopoulos, Philippe Moreau, Evangelos Terpos, PubMed	2021	118
Targeting <scp>BCL</scp>‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma Jonathan L. Kaufman, Cristina Gasparetto, Fredrik Schjesvold, American Journal of Hematology	2020	105

Page 1